(UroToday.com) One of the fastest moving disease spaces in prostate cancer in metastatic castration sensitive prostate cancer. While androgen-deprivation therapy (ADT) alone was the standard treatment five years ago, now there are a number of treatment options which have been shown to improve overall survival, including docetaxel, abiraterone acetate, enzalutamide, and apalutamide. TITAN was the pivotal phase III trial demonstrating the benefit of apalutamide in this disease space. In the primary analysis at 22.7 months median follow-up, treatment with apalutamide improved overall and radiographic progression-free survival while preserving health-related quality of life (HRQoL). After the publication of the primary results, the study was unblinded and patients who had not progressed on placebo could cross-over to apalutamide. In the Prostate, Testicular, Penile Poster session at the 2021 American Society of Clinical Oncology 2021 Annual Meeting held on Friday June 4th, 2021, Dr. Agarwal presented HRQoL data from this final analysis, after cross-over.